If you’re a member of the media working on a story about brain trauma or brain health, we can connect you with the experts at Cohen Veterans Bioscience. Please don’t hesitate to contact us.
Nicole Harmon, PhD
Executive Director, External Affairs
Cohen Veterans Bioscience
Cohen Veterans Bioscience is a nonprofit 501(c)(3) research organization dedicated to fast-tracking the development of diagnostic tests and personalized therapeutics for the millions of veterans and civilians who suffer the devastating effects of trauma-related and other brain disorders.
Follow Cohen Veterans Bioscience
- Read more
Cohen Veterans Bioscience announced it is extending its commitment to the brain health of Veterans by supporting the National Association of Veterans Research Education Foundation (NAVREF) and the new VA Office of Research and Development (ORD) led Partnered Research Program (PRP).
- Read more
This prize, which was first launched in 2017, will award €10,000 to the researcher/research group whose publication in neuroscience research best exemplifies data where the results do not confirm the expected outcomes or original hypotheses.
Cohen Veterans Bioscience Launches New Veterans Advisory Council (VAC) To Address Brain Health PrioritiesRead more
Cohen Veterans Bioscience announces its sponsorship for the formation of a Veterans Advisory Council (VAC) to ensure the delivery of meaningful results for Veterans through data-driven science and advocacy. The VAC will represent, advocate and support military and veterans’ interests to CVB, to Partners, and to the broader community engaged in the support, research, prevention, and treatment of these conditions.
- Read more
Cohen Veterans Bioscience announces that traumatic brain injuries (TBIs) – the grossly understudied “invisible wounds” afflicting today’s soldiers – are under-detected and under-treated.
Cohen Veterans Bioscience and Parexel Biotech Collaborate on Landmark Adaptive Platform Trial Studying Posttraumatic Stress Disorder (PTSD) PharmacotherapeuticsRead more
Cohen Veterans Bioscience announced its strategic collaboration with Parexel Biotech, a new division of Parexel, for CVB’s adaptive platform trial evaluating pharmacotherapeutics to treat PTSD.